Paper Details

  1. Home
  2. Paper Details

Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest through PI3K/Akt/NF-<i>&#954;</i>B Axis in Cancer Stem-Like Esophageal Squamous Cell Carcinoma Spheres.

Author: AfshariAmir R, AsadiJahanbakhsh, HashemySeyed Isaac, JavidHossein, Zahedi AvvalFarnaz

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Aprepitant, a neurokinin-1 receptor (NK1R) antagonist, showed strong antiproliferative and cytotoxic effects on esophageal squamous cancer cell (ESCC) spheres in vitro. The drug induced G2-M cell cycle arrest, activated caspase-dependent apoptosis, and abrogated the PI3K/Akt pathway. These results suggest that aprepitant may be effective in treating ESCC.
Paper Details　
Original Abstract of the Article :
The antagonists of the neurokinin-1 receptor (NK1R) are known for their anti-inflammatory, anxiolytic, antiemetic, and anticancer activities. Aprepitant, a nonpeptide NK1R antagonist, is used in nausea and vomiting, the most common side effects of cancer chemotherapy in patients. It has been establi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8677400/

データ提供：米国国立医学図書館（NLM）

Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest

The search for effective cancer treatments is an ongoing scientific quest. This study delves into the potential of aprepitant, a drug currently used to manage nausea and vomiting associated with chemotherapy, as a possible anticancer agent. This research, like a skillful archer aiming for a precise target, investigates the potential of aprepitant to combat cancer cells.

Aprepitant: A Potential Weapon Against Cancer?

The study reveals that aprepitant exhibits significant anticancer effects against esophageal squamous cell carcinoma (ESCC) spheres, a type of cancer stem cell. Aprepitant was found to induce caspase-dependent apoptotic cell death and G2/M cell cycle arrest in these cells. This finding, like a well-placed arrow striking its target, suggests that aprepitant might be a potent weapon in the fight against ESCC.

Health Implications and Applications

This study, like a flickering candle in the desert, offers a glimmer of hope for patients with ESCC. It suggests that aprepitant, a drug already approved for other uses, might hold therapeutic potential for this type of cancer. However, further research is needed to validate these findings in clinical trials and ensure the safe and effective use of aprepitant for cancer treatment.

Dr. Camel's Conclusion

This study, like a desert caravan venturing into uncharted territories, offers a promising new approach to fighting ESCC. It suggests that aprepitant, a drug previously known for its antiemetic properties, might be a valuable tool in the fight against cancer. Further research is needed to unlock the full potential of aprepitant and bring this promising treatment option to patients.

Date :
  1. Date Completed 2022-01-20
  2. Date Revised 2022-01-20
Further Info :

Pubmed ID

34926694

DOI: Digital Object Identifier

PMC8677400

Related Literature

Article Analysis
・Side Effects of aprepitant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.